SIFROL ER

Country: Ինդոնեզիա

language: ինդոնեզերեն

source: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

active_ingredient:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

MAH:

BOEHRINGER INGELHEIM INDONESIA - Indonesia

INN:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

dosage:

0.375 MG

pharmaceutical_form:

TABLET PELEPASAN LAMBAT

units_in_package:

DUS, 3 ALUBLISTER @ 10 TABLET PELEPASAN LAMBAT

manufactured_by:

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG., GERMANY - Federal Republic of Germany

authorization_date:

2020-11-05

SPC

PT. BOEHRINGER LNGCLHCIM INDONESIA
DRUG REGULATORY AFFAIRS DEPT.
1.
BASIC
PRODUCT INFORMATION
No. 0186-16
25 July 2012
SIFROL
®
PRAMIPEXOLE
COMPOSITION
1 tablet contains
0.125, 0.25 mg
(S)-2-amino-4,5,6,
7-tetrahydro-6-propylamino-benzothiazole dihydrochloride
monohydrate equivalent to 0.088, 0.18 mg pramipexole base
Exciplents:
mannltol, maize starch, anhydrous colloidal silica, polyvidone,
magnesium stearate
1 extended-release tablet contains
0.375, 0.75 mg
(S)-2-amino-4,5,6,
7-tetrahydro-6-propylamino-benzothiazole dihydrochloride
monohydrate equivalent to 0.26, 0.52 mg pramipexole base
Exciplents .. :
hypromellose 2208, maize starch, carbomer 941, colloidal anhydrous
silica, magnesium stearate
INDICATION
SIFROL
G
tablets and extended-release tablets are indicated for the treatment
of the signs
and symptoms of idiopathic parkinson's disease when the effect of
levodopa wears off or
becomes inconsistent and fluctuations of the therapeutic effect occur
(end of dose "on
off" fluctuations). It may be used alone (without levodopa) or in
combination with
levodopa.
�
;
�����
�
blets are indicated for the symptomatic treatme
r
t
.
�
f
�
�
io
,
�
at
��
-
C-
�
e
�
_
t
,
I
�
-
��
..
�
�
.
�
.
�
.
�
I '
Uf d� �fl;.:
............ .
DOSAGE AND ADMINISTRATION
,L
_.r_
_0_
_.��!_
_0_
_E' :.�.�._
_0_
_.: .. _
_�.�! _
_.. _
_� _
_.... ._
_(All dose information refers to pramipexole salt form) _
j : , , q, :� ll
h
·.:
.....
••.
••
•
....
.....
.
.
.
.. .
I
PARKINSON 'S DISEASE
Tablets
The tablets should be taken orally, swallowed with water, and can be
taken either with or
without food.
The daily dosage is administered in equally divided doses 3x per day.
Remarks: Yellow (CCDS 0186·13), blue (CCDS 0186-14), green (CCDS
0186-15), orange (CCDS 0186-16)
SIFROL
I')
CCDS 0186-16_ Reg May 12